Stifel initiated coverage on Oculis Holding AG with a new price target
$OCS
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2025 | $38.00 | Overweight | Analyst |
| 8/27/2025 | $36.00 | Buy | Needham |
| 12/5/2023 | $30.00 | Buy | Chardan Capital Markets |
| 10/5/2023 | $35.00 | Buy | Stifel |
| 6/14/2023 | $22.00 | Buy | BofA Securities |
| 6/12/2023 | $28.00 | Buy | H.C. Wainwright |
| 6/8/2023 | $58.00 | Outperform | Robert W. Baird |
| 5/10/2023 | $23.00 | Buy | Pareto |
6-K - Oculis Holding AG (0001953530) (Filer)
SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)
6-K - Oculis Holding AG (0001953530) (Filer)
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST. The 2026 Annual General Meeting will be held in-person and broadcast, with no option for virtual participation. To join the broadcast, please use the following link: https://meetings.lumiconnect.com/100-352-684-319. Information pertaining to the 2026 Annual General Meeting, including meeting materials, can be accessed on our website at https://investors.oculis.com/events-pre
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema (DME) has the potential to address significant unmet needs for early treatment intervention and for inadequate responders to the current standard of care2-4OCS-01 aims to transform the treatment paradigm as the first topical treatment for DME, a leading cause of vision loss in the working-age population in most developed countries1 ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations t
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in upcoming investor conferences in April. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio. 2026 promises to be a landmark year for the company in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: OCS-01 (DIAMOND Phase 3 trials) topline pivotal results in diabetic m
Analyst initiated coverage of Oculis Holding AG with a rating of Overweight and set a new price target of $38.00
Needham initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $36.00
Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST. The 2026 Annual General Meeting will be held in-person and broadcast, with no option for virtual participation. To join the broadcast, please use the following link: https://meetings.lumiconnect.com/100-352-684-319. Information pertaining to the 2026 Annual General Meeting, including meeting materials, can be accessed on our website at https://investors.oculis.com/events-pre
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual outcomes, significantly affecting function and quality of life Decision supported by positive Phase 2 ACUITY data showing substantial improvements in vision combined with anatomical and biological neuroprotective benefits in patients treated with Privosegtor Strong regulatory momentum bolsters the global development strategy, with PIONEER registrational program in optic neuropathies underway, potentially providing Privosegtor with an accelerated regulatory pathway ZUG, Switzerl
Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis' le
Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today announces the advancement of Privosegtor into a registrational program for neuro-ophtha
DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event
ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica
SC 13G - Oculis Holding AG (0001953530) (Subject)
SC 13G/A - Oculis Holding AG (0001953530) (Subject)